Cover Image
市場調查報告書

PharmaPoint:纖維肌痛 - 全球醫藥品預測、市場分析

PharmaPoint: Fibromyalgia - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 336854
出版日期 內容資訊 英文 220 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:纖維肌痛 - 全球醫藥品預測、市場分析 PharmaPoint: Fibromyalgia - Global Drug Forecast and Market Analysis to 2023
出版日期: 2015年05月01日 內容資訊: 英文 220 Pages
簡介

本報告提供全球纖維肌痛市場相關調查、纖維肌痛概要、治療藥的年度市場收益、年度成本、利用模式相關資料、10年的預測、未滿足需求、R&D、臨床試驗的評估、開發平台分析,及現在、未來的競爭狀況分析等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理學
  • 分類
  • 症狀
  • 生活品質

第4章 流行病學

  • 疾病的背景
  • 風險因素、共生病症
  • 全球趨勢
  • 預測手法
  • 纖維肌痛的流行病學性的預測
  • 討論

第5章 疾病管理

  • 診斷、治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 競爭評估

  • 概要
  • 產品簡介

第7章 未滿足需求、機會

  • 概要
  • 更有效且耐容性良好的治療
    • 未滿足需求
    • 差距分析
    • 機會
  • 藥物核準的增加
  • 醫生/患者認識的提高、早期診斷
  • 診斷工具

第8章 開發平台評估

  • 概要
  • 臨床試驗製圖
  • 臨床開發中的潛力藥物
  • 其他開發中的藥物

第9章 現在、未來的企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Pfizer
    • Eli Lilly
    • Forest Laboratories (Actavis)
    • 第一三共
    • Tonix Pharmaceuticals
    • Theravance Biopharma

第10章 市場展望

  • 全球市場
  • 美國
  • 歐盟5國
  • 日本

第11章 附錄

圖表

目錄
Product Code: GDHC109PIDR

The fibromyalgia market is relatively new and not yet established. Three drugs currently dominate the sales across the 7MM and form the core treatment options; Lyrica, Cymbalta and Savella are all approved in the US while only the former is approved in Japan. Since these drugs are also available in the 5EU for other indications, they are prescribed as off-label therapies. A handful of other genericized products also provide off-label usage including antidepressants, anti-epileptics, opioids and muscle relaxants. Although Lyrica, Cymbalta and Savella can provide an effective treatment regimen, there are ample opportunities for the development of alternative treatment choices which can expand the medications available to patients, providing improvement in efficacy, safety and compliance. By 2023, there will be four new entrants to the market (Lyrica CR, TNX-102 SL, DS-5565 and TD-9855). These new products will help to drive market growth and offset some of the patent expiries of the leading brands during the forecast period. Despite these advancements in the treatment landscape, fibromyalgia therapeutic sales growth are expected to be minimal.

Highlights

Key Questions Answered

  • The fibromyalgia market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the fibromyalgia market?
  • The late-stage fibromyalgia pipeline consists of reformulations of existing therapies, one of which has a novel route of administration, and me-too products. Which drug will have a significant impact on the fibromyalgia market? Which of these drugs will have the highest CAGR, and why?
  • How will the introduction of new therapies change the fibromyalgia treatment landscape? How will the drug treatment rates change over the next five years? What are the key drivers and barriers to this change?

Key Findings

  • The main driver of the expansion of the fibromyalgia market will be the introduction of four new therapies across the seven major markets.
  • The biggest barrier for the introduction of new therapies will be patent expirations of the leading brands marketed for fibromyalgia, which will result in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period.
  • The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively.

Scope

  • Overview of fibromyalgia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized fibromyalgia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the fibromyalgia therapeutics market.
  • Pipeline analysis: focus on the four late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global fibromyalgia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global fibromyalgia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global fibromyalgia therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global fibromyalgia therapeutics market from 2013-2018.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods - Total Prevalent Cases of Fibromyalgia
    • 4.4.4. Forecast Assumptions and Methods - Fibromyalgia Pain Severity
  • 4.5. Epidemiological Forecast for Fibromyalgia (2013-2023)
    • 4.5.1. Total Prevalent Cases of Fibromyalgia
    • 4.5.2. Age-Specific Total Prevalent Cases of Fibromyalgia
    • 4.5.3. Sex-Specific Total Prevalent Cases of Fibromyalgia
    • 4.5.4. Age-Standardized Total Prevalence of Fibromyalgia
    • 4.5.5. Total Prevalent Cases of Fibromyalgia by Pain Severity
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles
    • 6.2.1. Cymbalta (duloxetine)
    • 6.2.2. Savella (milnacipran)
    • 6.2.3. Lyrica (pregabalin)
    • 6.2.4. Neurontin (gabapentin)
    • 6.2.5. Other Antidepressants
    • 6.2.6. Opioids
    • 6.2.7. Cyclobenzaprine

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. More Effective and Well-Tolerated Therapies
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Increased Drug Approvals
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Increased Physician/Patient Awareness and Earlier Diagnosis
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Diagnostic Tools
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Class of Therapy
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Lyrica CR (pregabalin)
    • 8.3.2. DS-5565 (mirogabalin)
    • 8.3.3. TNX-102 SL (cyclobenzaprine)
    • 8.3.4. TD-9855
  • 8.4. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Pfizer
    • 9.3.2. Eli Lilly
    • 9.3.3. Forest Laboratories (Actavis)
    • 9.3.4. Daiichi Sankyo
    • 9.3.5. Tonix Pharmaceuticals
    • 9.3.6. Theravance Biopharma

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Fibromyalgia Patients
    • 11.4.2. Percentage of Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for This Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Fibromyalgia
  • Table 2: Comparison of the ACR Criteria for Fibromyalgia Classification
  • Table 3: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of Fibromyalgia
  • Table 4: 7MM, Sources of Fibromyalgia Pain Severity Data Used to Forecast the Total Prevalent Cases of Fibromyalgia Segmented by Pain Severity
  • Table 5: 7MM, Total Prevalent Cases of Fibromyalgia, Ages ≥10 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 6: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N (Row %), 2013
  • Table 7: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ≥10 Years, N (Row %), 2013
  • Table 8: 7MM Total Prevalent Cases of Fibromyalgia, N (%), by Pain Severity, Both Sexes, Ages ≥10 Years, 2013
  • Table 9: Treatment Guidelines for Fibromyalgia
  • Table 10: Most Commonly Prescribed Drugs for Fibromyalgia by Class in the Global Markets, 2014
  • Table 11: Diagnosis and Treatment of Fibromyalgia, Country Profile - US
  • Table 12: Diagnosis and Treatment of Fibromyalgia, Country Profile - France
  • Table 13: Diagnosis and Treatment of Fibromyalgia, Country Profile - Germany
  • Table 14: Diagnosis and Treatment of Fibromyalgia, Country Profile - Italy
  • Table 15: Diagnosis and Treatment of Fibromyalgia, Country Profile - Spain
  • Table 16: Diagnosis and Treatment of Fibromyalgia, Country Profile - UK
  • Table 17: Diagnosis and Treatment of Fibromyalgia, Country Profile - Japan
  • Table 18: Leading Branded Drug Treatments for Fibromyalgia in the 7MM, 2014
  • Table 19: Product Profile - Cymbalta
  • Table 20: Cymbalta SWOT Analysis, 2014
  • Table 21: Global Sales Forecasts ($m) for Cymbalta, 2013-2023
  • Table 22: Product Profile - Savella
  • Table 23: Savella SWOT Analysis, 2014
  • Table 24: Global Sales Forecasts ($m) for Savella, 2013-2023
  • Table 25: Product Profile - Lyrica
  • Table 26: Lyrica SWOT Analysis, 2014
  • Table 27: Global Sales Forecasts ($m) for Lyrica, 2013-2023
  • Table 28: Product Profile - Neurontin
  • Table 29: Neurontin SWOT Analysis, 2014
  • Table 30: Global Sales Forecasts ($m) for Gabapentin, 2013-2023
  • Table 31: Product Profile - Other Antidepressants Frequently Used in the Treatment of Fibromyalgia
  • Table 32: Other Antidepressants Used in the Treatment of Fibromyalgia, SWOT Analysis, 2014
  • Table 33: Global Sales Forecasts ($m) for Other Antidepressants, 2013-2023
  • Table 34: Product Profile - Opioids
  • Table 35: Opioids SWOT Analysis, 2014
  • Table 36: Global Sales Forecasts ($m) for Opioids, 2013-2023
  • Table 37: Product Profile - Cyclobenzaprine
  • Table 38: Cyclobenzaprine SWOT Analysis, 2014
  • Table 39: Global Sales Forecasts ($m) for Cyclobenzaprine, 2013-2023
  • Table 40: Unmet Need and Opportunity in Fibromyalgia
  • Table 41: Comparison of Therapeutic Classes in Development for Fibromyalgia, 2014
  • Table 42: Product Profile - Lyrica CR (pregabalin)
  • Table 43: Lyrica CR SWOT Analysis, 2014
  • Table 44: Global Sales Forecasts ($m) for Lyrica CR, 2013-2023
  • Table 45: Product Profile - DS-5565 (mirogabalin)
  • Table 46: DS-5565 SWOT Analysis, 2014
  • Table 47: Global Sales Forecasts ($m) for DS-5565, 2013-2023
  • Table 48: Product Profile - TNX-102 SL (Cyclobenzaprine)
  • Table 49: SWOT Analysis TNX-102 SL, 2014
  • Table 50: Global Sales Forecasts ($m) for TNX-102 SL, 2013-2023
  • Table 51: Product Profile - TD-9855
  • Table 52: TD-9855 SWOT Analysis, 2014
  • Table 53: Global Sales Forecasts ($m) for TD-9855, 2013-2023
  • Table 54: Drugs in Development for Fibromyalgia, 2014
  • Table 55: Key Companies in the Fibromyalgia Market in the 7MM, 2014
  • Table 56: Pfizer's Fibromyalgia Portfolio Assessment, 2014
  • Table 57: Eli Lilly's Fibromyalgia Portfolio Assessment, 2014
  • Table 58: Forest Laboratories' (Actavis) Fibromyalgia Portfolio Assessment, 2014
  • Table 59: Daiichi Sankyo's Fibromyalgia Portfolio Assessment, 2014
  • Table 60: Tonix Pharmaceutical's Fibromyalgia Portfolio Assessment, 2014
  • Table 61: Theravance Biopharma's Fibromyalgia Portfolio Assessment, 2014
  • Table 62: Global Sales Forecasts ($m) for Fibromyalgia, 2013-2023
  • Table 63: Global Fibromyalgia Market - Drivers and Barriers, 2013-2023
  • Table 64: Sales Forecasts ($m) for Fibromyalgia in the US, 2013-2023
  • Table 65: Key Events Impacting Sales for Fibromyalgia in the US, 2013-2023
  • Table 66: Fibromyalgia Market in the US - Drivers and Barriers, 2013-2023
  • Table 67: Sales Forecasts ($m) for Fibromyalgia in the 5EU, 2013-2023
  • Table 68: Key Events Impacting Sales for Fibromyalgia in the 5EU, 2013-2023
  • Table 69: Fibromyalgia Market in the 5EU - Drivers and Barriers, 2013-2023
  • Table 70: Sales Forecasts ($m) for Fibromyalgia in Japan, 2013-2023
  • Table 71: Key Events Impacting Sales for Fibromyalgia in the US, 2013-2023
  • Table 72: Fibromyalgia Market - Drivers and Barriers, 2013-2023
  • Table 73: Key Launch Dates for Fibromyalgia Drugs in the 7MM
  • Table 74: Key Patent Expiries for the Marketed Drugs Indicated for Fibromyalgia
  • Table 75: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of Fibromyalgia Ages ≥10 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N, 2013
  • Figure 3: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ≥10 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Total Prevalence of Fibromyalgia (%), Ages ≥10 Years, by Sex, 2013
  • Figure 5: 7MM Total Prevalent Cases of Fibromyalgia (N), by Pain Severity, Both Sexes, Ages ≥10 Years, 2013
  • Figure 6: Fibromyalgia Tender Points
  • Figure 7: Fibromyalgia Therapeutics - Class of Therapy, 2014
  • Figure 8: Fibromyalgia - Phase II-III Pipeline, 2014
  • Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in Fibromyalgia, 2013-2023
  • Figure 10: Clinical and Commercial Positioning of Lyrica CR
  • Figure 11: Clinical and Commercial Positioning of DS-5565
  • Figure 12: Clinical and Commercial Positioning of TNX-102 SL
  • Figure 13: Clinical and Commercial Positioning of TD-9855
  • Figure 14: Global Sales of Branded Products for Fibromyalgia by Company, 2013-2023
  • Figure 15: Company Portfolio Gap Analysis in Fibromyalgia, 2013-2023
  • Figure 16: Pfizer's SWOT Analysis in Fibromyalgia, 2013-2023
  • Figure 17: Eli Lilly SWOT Analysis in Fibromyalgia, 2013-2023
  • Figure 18: Forest Laboratories (Actavis) SWOT Analysis in Fibromyalgia, 2013-2023
  • Figure 19: Daiichi Sankyo SWOT Analysis in Fibromyalgia, 2013-2023
  • Figure 20: Tonix Pharmaceuticals SWOT Analysis in Fibromyalgia, 2013-2023
  • Figure 21: Theravance Biopharma SWOT Analysis in Fibromyalgia, 2013-2023
  • Figure 22: Global Sales for Fibromyalgia by Region, 2013-2023
  • Figure 23: Sales for Fibromyalgia in the US by Drug Class, 2013-2023
  • Figure 24: Sales for Fibromyalgia in the 5EU by Drug Class, 2013-2023
  • Figure 25: Sales for Fibromyalgia in the 5EU by Country, 2013-2023
  • Figure 26: Sales for Fibromyalgia in Japan by Drug Class, 2013-2023
Back to Top